Business Context and Reporting Period
Company: Lucid Diagnostics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 13, 2024
Event: Unregistered sales of equity securities and material modification to rights of security holders.
Key Financial Metrics and Transaction Details
This filing reports a capital raise rather than operational financial results. Key metrics include:
- Aggregate Gross Proceeds: $18.16 million.
- Series B Preferred Stock Issued: 44,285 shares total outstanding immediately after the transaction.
- Transaction Components:
- Sale of 12,495 new Series B shares at $1,000 per share.
- Exchange of 13,625 Series A shares and 10,670 Series A-1 shares for 31,790 Series B shares.
- Included $5.67 million in proceeds from Series A-1 shares immediately exchanged for Series B.
- Capital Structure Impact: Post-transaction, the Company has no outstanding Series A or Series A-1 Preferred Stock.
Material Changes Versus Prior Period
The filing details a significant restructuring of the Company's preferred stock capitalization:
- Elimination of Prior Series: All outstanding Series A and Series A-1 Convertible Preferred Stock were exchanged or retired.
- New Senior Security: Introduction of Series B Convertible Preferred Stock, which ranks senior to Common Stock.
- Authorization Increase: The number of shares designated as Series A-1 Preferred Stock was increased by 5,670 shares to facilitate the immediate exchange.
Terms, Outlook, and Risks
Key Terms of Series B Preferred Stock:
- Conversion: Convertible at holder option after six months at an initial price of $1.2444 per share of Common Stock. Automatic conversion occurs on March 13, 2026, upon fundamental transactions, or upon a "VWAP-Based Mandatory Conversion Event" (VWAP $\ge$ $8.00 for 20 of 30 days).
- Dividends: Payable in Common Stock equal to 20% of the shares issuable upon conversion on March 13, 2025, and March 13, 2026. Dividends are accelerated upon fundamental transactions.
- Liquidation Preference: Holders receive the greater of the Stated Value ($1,000) plus accrued dividends, or the amount payable if converted immediately prior to liquidation.
- Voting: Voting rights on an "as converted" basis.
- Limitations: Beneficial ownership limitation of 4.99% (or 9.99% at election) and a primary market limitation tied to the 19.99% Nasdaq Market Limit.
Risks and Contingencies:
- Registration Rights: The Company agreed to file a registration statement for the resale of Common Stock issuable upon conversion.
- Exemption Status: The offering was exempt from registration under Section 4(a)(2) and Rule 506 of Regulation D; securities are restricted and cannot be resold without registration or an exemption.
Investor Verification Checklist
- Verify the exact number of Series B shares outstanding (44,285) and the elimination of Series A/A-1 stock.
- Confirm the initial conversion price of $1.2444 and the conditions for the mandatory conversion trigger ($8.00 VWAP).
- Review the dividend schedule (20% of conversion shares in 2025 and 2026) and its impact on future dilution.
- Check the status of the Registration Rights Agreement and the filing of the registration statement for resale.
- Assess the impact of the 4.99% beneficial ownership limitation on investor exit strategies.